glp receptor 1 agonists GLP-1 for individualized treatment of type 2 diabetes mellitus GLP-1 Receptor Agonists in Solid

Stay hydrated GLP-1 medications often reduce thirst cues

[2] Research indicates that ALA may improve symptoms of diabetic neuropathy: for example, clinical trials and meta-analyses have shown that intravenous ALA (typically 600 mg per day for 3 weeks) may significantly reduce neuropathic pain, paresthesia, and numbness in diabetic patients

Blood Sugar Control Phase 2 data showed HbA1c reductions of up to 2.02% at the 12mg dose

[1] [2] The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment

25,26 There was no significant difference in diabetic retinopathy between placebo and GLP-1RAs, except for an increased risk with subcutaneous semaglutide (OR 1.75